Delivery of anti-migraine compounds through an inhalation route
First Claim
1. A composition for delivery of lidocaine consisting of a condensation aerosol a) formed by volatilizing a thin layer of lidocaine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of lidocaine and condensing the heated vapor of lidocaine to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% lidocaine degradation products, and c) the condensation aerosol has an MMAD of less than 3 microns.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering lidocaine, verapamil, diltiazem, isometheptene, or lisuride through an inhalation route is provided which comprises: a) a thin coating of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
30 Claims
-
1. A composition for delivery of lidocaine consisting of a condensation aerosol
a) formed by volatilizing a thin layer of lidocaine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of lidocaine and condensing the heated vapor of lidocaine to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% lidocaine degradation products, and c) the condensation aerosol has an MMAD of less than 3 microns.
-
4. A composition for delivery of verapamil consisting of a condensation aerosol
a) formed by volatilizing a thin layer of verapamil on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of verapamil and condensing the heated vapor of verapamil to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% verapamil degradation products, and c) the condensation aerosol has an MMAD of less than 3 microns.
-
7. A composition for delivery of diltiazem consisting of a condensation aerosol
a) formed by volatilizing a thin layer of diltiazem on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of diltiazem and condensing the heated vapor of diltiazem to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% diltiazem degradation products, and c) the condensation aerosol has an MMAD of less than 3 microns.
-
10. A composition for delivery of isometheptene consisting of a condensation aerosol
a) formed by volatilizing a thin layer of isometheptene on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of isometheptene and condensing the heated vapor of isometheptene to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% isometheptene degradation products, and c) the condensation aerosol has an MMAD of less than 3 microns.
-
13. A composition for delivery of lisuride consisting of a condensation aerosol
a) formed by volatilizing a thin layer of lisuride on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of lisuride and condensing the heated vapor of lisuride to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% lisuride degradation products, and c) the condensation aerosol has an MMAD of less than 3 microns.
-
16. A method of producing lidocaine in an aerosol form comprising:
-
a. heating a thin layer of lidocaine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the lidocaine to form a heated vapor of the lidocaine, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the lidocaine comprising less than 5% lidocaine degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (17, 18)
-
-
19. A method of producing verapamil in an aerosol form comprising:
-
a. heating a thin layer of verapamil on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the verapamil to form a heated vapor of the verapamil, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the verapamil comprising less than 5% verapamil degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (20, 21)
-
-
22. A method of producing diltiazem in an aerosol form comprising:
-
a. heating a thin layer of diltiazem on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the diltiazem to form a heated vapor of the diltiazem, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the diltiazem comprising less than 5% diltiazem degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (23, 24)
-
-
25. A method of producing isometheptene in an aerosol form comprising:
-
a. heating a thin layer of isometheptene on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the isometheptene to form a heated vapor of the isometheptene, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the isometheptene comprising less than 5% isometheptene degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (26, 27)
-
-
28. A method of producing lisuride in an aerosol form comprising:
-
a. heating a thin layer of lisuride on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the lisuride to form a heated vapor of the lisuride, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the lisuride comprising less than 5% lisuride degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (29, 30)
-
Specification